GHENT, BELGIUM--(Marketwire - October 13, 2010) -
GHENT, Belgium, 13 October 2010 - Ablynx [Euronext Brussels: ABLX] today announced that the first symposium specifically dedicated to single domain antibodies will take place in Ghent on 14 and 15 October 2010.
The aim of this first symposium focused solely on single domain antibody technologies is to create a forum that allows researchers from academia and industry to discuss the latest developments in the field of single domain antibodies. The symposium will cover all aspects of research from basic innovation through to clinical development.
Over the past few years, there has been growing excitement about the application of certain single domain antibodies due to their intrinsic properties including their small size, robustness, potential to generate multivalent and multispecific constructs and their capability to target molecules that are outside the reach of classical antibodies.
Today, single domain antibodies have come of age with an increasing number in preclinical and clinical development and they are anticipated by many to become the next generation of antibody-based biologics.
For further information on the 1st symposium “Single Domain Antibodies Come of Age”, which will take place in Ghent on 14-15 October 2010, please visit the home page of Ablynx’s website http://www.ablynx.com.
-ends-
About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 250 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007 and raised EUR50 million through an SPO in March 2010.
Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer’s disease.
For more information, please contact Ablynx: Dr. Edwin Moses Chairman and CEO t: +32 (0)9 262 00 07 m: +44 (0)7771 954 193 / +32 (0)473 39 50 68 e: edwin.moses@ablynx.com Eva-Lotta Allan Chief Business Officer t: +32 (0)9 262 00 75 m: +32 (0)475 78 36 21 / +44 (0)7990 570 900 e: eva-lotta.allan@ablynx.com
[HUG#1451673]
Complete version of the press release: http://hugin.info/137912/R/1451673/392755.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
